Page 113 - EKMUD Erişkin Bağışıklama Rehberi 2024

Erişkin Bağışıklama Rehberi 2024

4.4.4.6. kızamık-kabakulak-kızamıkçık (kkk) aşısı: İmmünsupresif/immün-
modulatuvar tedavi alan hastalarda kontrendikedir. Risk faktörleri olanlarda uzman
görüşü alınarak aşılama değerlendirilmelidir.
4.4.4.7. Human papillomavirüs (HPv) aşısı: Otoimmün/enflamatuvar romatiz-
mal hastalığı olan bireyler özellikle SLE hastaları genel popülasyon için öneriler doğ-
rultusunda HPV için aşılanmalıdır.

4.4.4.8. meningokok aşısı: Erişkin aşı şeması geçerlidir. Aspleni (elektif splenek-
tomi ve persistan kompleman eksiklikleri dahil) durumlarında kuadrivalan konjuge
meningokok aşısı yapılmalıdır. Ekulizumab alacak olan hastalarda meningokokal has-
talık riski belirgin şekilde artmıştır. Bu nedenle MenACWY ve MenB aşıları yapılmalıdır.
4.4.4.9. sars-Cov-2 aşılaması: Romatizmal hastalığı olan bireyler, klinik olarak
mümkünse immünmodülatör/immünsupresif tedavi öncesi aşılanmalıdır.

kaYnaklar
1. Blumentals WA, Arreglado A, Napalkov P, et al. Rheumatoid arthritis and the incidence of inf-
luenza and influenza-related complications: A retrospective cohort study. BMC Musculoskelet
Disord 2012;13:158. https://doi.org/10.1186/1471-2474-13-158
2. Falagas ME, Manta KG, Betsi GI, et al. Infection-Related morbidity and mortality in patients with
connective tissue diseases: A systematic review. Clin Rheumatol 2007;26:663-70. https://doi.
org/10.1007/s10067-006-0441-9
3. Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infec-
tions in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): A systemic
literature review informing the 2019 update of the EULAR recommendations for vaccinati-
on in adult patients with AIIRD. RMD Open 2019;5:e001041. https://doi.org/10.1136/rmdo-
pen-2019-001041
4. Kroon FPB, Najm A, Alunno A , et al. Risk and prognosis of SARS-CoV-2 infection and vacci-
nation against SARS-CoV-2 in rheumatic and musculoskeletal diseases: A systematic literatu-
re review to inform EULAR recommendations Ann Rheum Dis 2022;81(3):422-32. https://doi.
org/10.1136/annrheumdis-2021-221575
5. Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on
vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Ann Rheum Dis 2021;80:1255-65. https://doi.org/10.1136/annrheumdis-2021-221244
6. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vacci-
nation in adult patients with autoimmune inflammatory rheumatic diseases Ann Rheum Dis
2020;79(1):39-52. https://doi.org/10.1136/annrheumdis-2019-215882
7. Rondaan C, Furer V, Heijstek MW, et al. Efficacy, immunogenicity and safety of vaccination in
adult patients with autoimmune inflammatory rheumatic diseases: A systematic literature re-
view for the 2019 update of EULAR recommendations. RMD Open 2019;5(2):e001035. https://
doi.org/10.1136/rmdopen-2019-001035
8. Landewé RBM, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and
vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-
CoV-2: The November 2021 update. Ann Rheum Dis 2022; Online ahead of print.
9. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are
severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum
2010;62:75-81. https://doi.org/10.1002/art.25033
10. Bühler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with au-
92 toimmune inflammatory rheumatic diseases. Swiss Med Wkly 2015;145:w14159. https://doi.
org/10.4414/smw.2015.14159